CareDx Q2 2023 revenue $70.3M (-13% YoY); net loss $0.46 per share vs $0.41 loss last year

CareDx, Inc.

2023-Q2 EPS reported -$0.91 revenue$147,563,000

Testing services revenue $53.4M, down 20% YoY due to Medicare Billing Article revisions.
Patient and Digital Solutions revenue $9.0M (+33% YoY); Products revenue $7.9M (+17% YoY).
AlloMap and AlloSure test results ~37,500 (-17% YoY); over 80% adoption of new requisition forms.
Received first multimodal MolDX approval for HeartCare and first dd-cfDNA MolDX approval for AlloSure Lung.
Full year 2023 revenue guidance $240M-$260M; cash and equivalents $283M, no debt.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.